Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579526 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers
A Phase 1 study, sponsored by Avalo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01579526 is a Phase 1 study that has completed, run by Avalo Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT01579526, a Phase 1 study, has completed, sponsored by Avalo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and pharmacokinetics of FP01 in healthy volunteers.
Interventions
- DRUG FP01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579526
The ClinicalTrials.gov registry entry for NCT01579526 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avalo Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FP01 is the first listed.
NCT01579526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01579526 about?
NCT01579526 is a clinical study titled "A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers". The purpose of this study is to determine the safety and pharmacokinetics of FP01 in healthy volunteers.
What is the current status of trial NCT01579526?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2012-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01579526?
The interventions under investigation include: FP01 (DRUG).
Who is sponsoring clinical trial NCT01579526?
This trial is sponsored by Avalo Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.